Cathepsin B and L inhibitors: a patent review (2010 - present)

References

• Kim W, Kang K. Recent developments of cathepsin inhibitors and their selectivity. Expert Opin Ther Pat. 2002;12:419–432.
   Web of Science ®Google Scholar
• Grabowska UB, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Disc. 2005;8:619–630.
   PubMedGoogle Scholar
• Thurmond RL, Sun S, Karlsson L, et al. Cathepsin S inhibitors as novel immunomodulators. Curr Opin Invest Dr. 2005;6:473–482.
   PubMedGoogle Scholar
• Frizler M, Stirnberg M, Sisay MT, et al. Development of nitrile-based peptidic inhibitors of cysteine cathepsins. Curr Top Med Chem. 2010;10:294–322.
   PubMed Web of Science ®Google Scholar
• Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat. 2011;2:311–337.
   Web of Science ®Google Scholar
• Hernandez AA, Roush WR. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr Opin Chem Biol. 2002;6:459–465.
   PubMed Web of Science ®Google Scholar
• Biniossek ML, Nägler DK, Becker-Pauly C, et al. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J Proteome Res. 2011;10:5363–5373.
   PubMed Web of Science ®Google Scholar
• Illy C, Quraishi O, Wang J, et al. Role of the occluding loop in cathepsin B activity. J Biol Chem. 1997;272:1197–1202.
   PubMed Web of Science ®Google Scholar
• Musil D, Zucic D, Turk D, et al. The refined 2.15-A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. Embo J. 1991;10:2321−30.
   PubMed Web of Science ®Google Scholar
• Almeida PC, Nantes IL, Chagas JR, et al. Cathepsin B activity regulation-heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation. J Biol Chem. 2001;276:944–951.
   PubMed Web of Science ®Google Scholar
• Cotrin SS, Puzer L, Judice WAD, et al. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. Anal Biochem. 2004;335:244–252.
   PubMed Web of Science ®Google Scholar
• Schenker P, Alfarano P, Kolb P, et al. A double headed cathepsin B inhibitor devoid of warhead. Protein Sci. 2008;17:2145–2155.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Li T, Bartz U, et al. Cathepsin B inhibitors: combining dipeptide nitriles with an occluding loop recognition element by click chemistry. ACS Med Chem Lett. 2016;7:211–216.
   PubMed Web of Science ®Google Scholar
• Shah PP, Wang T, Kaletsky RL, et al. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol. 2010;78:319–324.
   PubMed Web of Science ®Google Scholar
• Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. BBA-Proteins Proteom. 2012;1824:68–88.
   PubMed Web of Science ®Google Scholar
• Kaletsky RL, Simmons G, Bates P. Proteolysis of the ebola virus glycoproteins enhances virus binding and infectivity. J Virol. 2007;81:13378–13384.
   PubMed Web of Science ®Google Scholar
• Pager CT, Craft WW, Patch J, et al. A mature and fasogenic form of the nipah requires proteolytic processing by virus fusion protein cathepsin L. J Virol. 2006;346:251–257.
   Web of Science ®Google Scholar
• University of Illinois. Methods for inhibiting viruses by targeting cathepsin-L cleavage sites in the viruses glycoproteins. WO 2013152223A2 (2013); also published as US 20150150878A1 (2015).
   Google Scholar
• Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011;85:873–882.
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658–12664.
   PubMed Web of Science ®Google Scholar
• Gong YS, Chang L, Viola KL, et al. Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. P Natl Acad Sci USA. 2003;100:10417–10422.
   PubMed Web of Science ®Google Scholar
• Hook V, Toneff T, Bogyo M, et al. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer’s disease. Biol Chem. 2005;386:931–940.
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada, Ltd. Preparation of diarylalkynyltrifluoroethyl sulfonylalaninamides as cathepsin B inhibitors. US 2010004871A1 (2010); also published as WO 2008037072A1 (2008), EP 2076490A1 (2009).
   Google Scholar
• Merck Frosst Canada, Ltd. preparation of phenylalanine cyanomethylamides as cathepsin B inhibitors. WO 2010069069A1 (2010).
   Google Scholar
• Virobay Inc. Preparation of fluoroalkyl amino acid amides as inhibitors of cathepsin B, K, L, F, or S. WO 2010056877A2 (2010); also published as WO 2010056877A3 (2010), CA 2743749A1 (2010), EP 2361243A2 (2011), EP 2361243 (2013), CN 102264695A (2011), CN 102264695B (2014), JP 2012508758T (2012), JP 5540004B2 (2014), IN 2011KN02004A (2011).
   Google Scholar
• Hoffman La Roche Inc. Preparation of proline dipetidyl nitrile derivatives as cathepsin particularly cathepsin S and L inhibitor. US 8163793B2 (2010); also published as US 20100267722A1 (2010), CA 2758210A1 (2010), WO 2010121918A1 (2010), AU 2010241084A1 (2011), AU 2010241084B2 (2014), KR 2011140136A (2011), KR 1320790B1 (2013), EP 2421826A1 (2012), EP 2421826B1 (2013), CN 102405211A (2012), CN 102405211B (2015), JP 2012524116T (2012), JP 5518997B2 (2014), NZ 595073A (2012), IL 215065A (2013), ES 2436550T3 (2014), PT 2421826E (2014), RU 2535479C2 (2014).
   Google Scholar
• Hoffman La Roche Inc. Novel pyridine derivatives as cathepsin inhibitors and their preparation. US 20150307472A1 (2015); also published as WO 2014029722A1 (2014), CA 2879796A1 (2014), AU 2013305102A1 (2015), IL 237128A (2015), KR 2015044947A (2015), CN 104583198A (2015), EP 2888244A1 (2015), JP 201553099T (2015), AR 92172A1 (2015), IN 2015DN00962A (2015), CR 20150073A (2015), MX 2015002026A (2015).
   Google Scholar
• Hoffman La Roche Inc. Novel cyclopentane derivatives as cysteine protease cathepsin inhibitors and their preparation use in the treatment of diseases. US 7893099B2 (2011); also published as WO 2010142650A1 (2010), US 20100317647A1 (2010), CA 2762619A1 (2010), AU 2010257586A1 (2011), AU 2010257586B2 (2015), KR 2012034727A (2012), EP 2440521A1 (2012).
   Google Scholar
• Loeser R, Frizler M, Schilling K, et al. Azadipeptide nitriles: highly potent and proteolytically stable inhibitors of papain-like cysteine proteases. Angew Chem Int Edit. 2008;47:4331–4334.
   PubMed Web of Science ®Google Scholar
• Jilin University. Preparation of hydrazine nitrile compounds as cathepsin inhibitors. CN 102731344A (2012). also published as CN 102731344B (2014).
   Google Scholar
• Frizler M, Lohr F, Furtmann N, et al. Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors. J Med Chem. 2011;54:396–400.
   PubMed Web of Science ®Google Scholar
• Jilin University. Hydrazine nitriles as cathepsin K inhibitor and their preparation use in the treatment of osteoporosis. CN 103086923B (2013).
   Google Scholar
• Viro Bay Inc. Preparation of substituted 2-(1-phenylethylamino)-3-phenylpropanamide derivatives as cathepsin inhibitors. US 20140256698A1 (2014); also published as WO 2014164844A1 (2014), US 20150191459A1 (2015).
   Google Scholar
• Viro Bay Inc. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain. US 8680152B2 (2014); also published as WO 2012151319A1 (2012), US 20120282267A1 (2012).
   Google Scholar
• Viro Bay Inc. Preparation of prolyl peptides as HCV inhibitors. US 20070054864A1 (2007); also published as US 7608592B2 (2009), AU 2006265632A1 (2007), AU 2006265632B2 (2012), CA 2613112A1 (2007), WO 2007005838A2 (2007), WO 2007005838A3 (2008), KR 2008027803A (2008), KR 1369872B1 (2014), EP 1906945A2 (2008), EP 1906945B1 (2015), CN 101242816A (2008), CN 101242816B (2012), JP 2009500353T (2009), JP 5368089B2 (2013), ZA 2007011069 (2009), EA 15415B1 (2011), NZ 564257A (2012), EP 2431379A2 (2012).
   Google Scholar
• Viro Bay Inc. Preparation of peptides as inhibitors of cathepsin B. US 8211897B2 (2012); also published as WO 2009100225A1 (2009), CA 2713108A1 (2009), US 20090203629A1 (2009), EP 2237793A1 (2010), CN 101969973A (2011), CN 101969973B (2015), JP 2011511089T (2011), JP 5718647B2 (2015), JP 2015051985A (2015), BR 200900772A2 (2015), MX 2010008371A (2010).
   Google Scholar
• Amura Therapeutics Ltd. Preparation of furopyrrolyl amino acid amides as dual cathepsin S and K inhibitors. WO 2009112839A1 (2009).
   Google Scholar
• Gruenental GMB. 3-Oxo-tetrahydro-furo[3,2-b]pyrrol-4(5H)-yl derivatives I as cathepsin inhibitors and their preparation. WO 2015161928A1 (2015); also published as US 20150307507A1 (2015).
   Google Scholar
• Xu M, Yang L, Rong JG, et al. Inhibition of cysteine cathepsin B and L activation in astrocytes contributes to neuroprotection against cerebral ischemia via blocking the tBid-mitochondrial apoptotic signaling pathway. Glia. 2014;62:855–880.
   PubMed Web of Science ®Google Scholar
• Soochow University. 2-(3,5-dimethoxybenzylidene) cyclopentanone, A novel synthetic small-molecule compound, provides effectes against ischemic stroke. CN 103330708A (2013).
   Google Scholar
• The University of Pennsylvania. Inhibitors of human cathepsin L, cathepsin B and cathepsin S and therapeutic uses thereof. US 20110207726A1 (2011); as WO 2009136997A2 (2009), WO 2009136997A3 (2009).
   Google Scholar
• Katunuma N, Murata E, Kakegawa H, et al. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. Febs Lett. 1999;458:6–10.
   PubMed Web of Science ®Google Scholar
• Research Foundation of the city, University of New York. Vinyl sulfonate ester inhibitors of cathepsin L inhibitors and their analytical uses. US 2015337286A1 (2015).
   Google Scholar
• Rosser CJ, Gaar M, Porvasnik S. Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?. BMC Cancer. 2009;9:225.
   Web of Science ®Google Scholar
• Xiang B, Fei X, Zhuang W, et al. Cathepsin L is involved in 6-hydroxydopamine induced apoptosis of SH-SY5Y neuroblastoma cells. Brain Res. 2011;1387:29–38.
   PubMed Web of Science ®Google Scholar
• Soochow University. Application of cathepsin L inhibitor in preparing radiotherapy sensitizing agents. CN 102423489A (2012).
   Google Scholar
• University of Ljubljana. 8-hydroxyquinolines as inhibitors of cathepsin B. EP 2353599A1 (2010); also published as WO 2011091973A1 (2011).
   Google Scholar
• Sosic I, Mirkovic B, Arenz K, et al. Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives. J Med Chem. 2013;56:521−33.
   PubMed Web of Science ®Google Scholar
• Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. Cathepsin B inhibitors. CN 103006621A (2012).
   Google Scholar
• Zhou YJ, Gao W, Rong Q, et al. Modular pathway engineering of diterpenoid synthases and the mevalonic acid pathway for miltiradiene production. J Am Chem Soc. 2012;134:3234–3241.
   PubMed Web of Science ®Google Scholar
• Kunming University of Science and Technology. Black orbit toad bladder inhibition and their gene. CN 103172730B (2014).
   Google Scholar